Future topics IMI Calls for proposals
The Innovative Medicines Initiative (IMI) has published three topics that are under consideration for inclusion in the Calls for proposals, that will be launched in 2014 under IMI 2:
Translational approaches to disease modifying therapy of Type 1 Diabetes Mellitus (T1DM): A pan-European group of endocrine clinics currently engaged in T1DM care is invited to establish a biomarker cluster capable of banking tissue samples and conducting comprehensive phenotypical profiling of people with T1DM. This activity could lead to a revised taxonomy of T1DM;
Discovery and validation of novel endpoints in retinal diseases: The aim of the project is to evaluate novel endpoint candidates for retinal diseases, mainly dry AMD and DR. The evaluation should cover the technical, medical and a health economic appropriateness of a method and bridge preclinical and clinical studies;
RADAR: Remote assessment of disease and relapse: The overall objective of the RADAR project is to develop and validate the science and regulatory approach of using remote assessment to derive biosignatures that characterise disease and predict changes in disease state to support pre-emptive treatment.
All information above is indicative and subject to the approval of the IMI 2 legislative package and the agreement of the IMI Governing Board on the Call topics.
IMI 2 will build on the successes and lessons learnt under IMI. Like IMI, it will bring together companies, universities, public laboratories, innovative small and medium-sized enterprises (SMEs), patient groups and regulators in collaborative projects that will pave the way for breakthrough vaccines, medicines and treatments to tackle Europe’s growing health challenges, and secure the future international competitiveness of Europe’s pharmaceutical industry.